Literature DB >> 23708510

Bringing target-matched PI3King from the bench to the clinic.

Filip Janku.   

Abstract

Entities:  

Keywords:  AKT; KRAS; MEK; PI3K; PIK3CA; PTEN; mTOR

Mesh：

Substances：

Year:  2013        PMID： 23708510      PMCID： PMC3735689          DOI： 10.4161/cc.25118

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  8 in total

1.  BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

Authors:  Anthony C Faber; Ryan B Corcoran; Hiromichi Ebi; Lecia V Sequist; Belinda A Waltman; Euiheon Chung; Joao Incio; Subba R Digumarthy; Sarah F Pollack; Youngchul Song; Alona Muzikansky; Eugene Lifshits; Sylvie Roberge; Erik J Coffman; Cyril H Benes; Henry L Gómez; José Baselga; Carlos L Arteaga; Miguel N Rivera; Dora Dias-Santagata; Rakesh K Jain; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2011-07-22       Impact factor: 39.397

2.  PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Authors:  Filip Janku; Apostolia M Tsimberidou; Ignacio Garrido-Laguna; Xuemei Wang; Rajyalakshmi Luthra; David S Hong; Aung Naing; Gerald S Falchook; John W Moroney; Sarina A Piha-Paul; Jennifer J Wheler; Stacy L Moulder; Siqing Fu; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

3.  PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.

Authors:  Jeanette Dupont Jensen; Anne-Vibeke Laenkholm; Ann Knoop; Marianne Ewertz; Raj Bandaru; Weihua Liu; Wolfgang Hackl; J Carl Barrett; Humphrey Gardner
Journal:  Clin Cancer Res       Date:  2010-10-12       Impact factor: 12.531

4.  Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.

Authors:  Federica Di Nicolantonio; Sabrina Arena; Josep Tabernero; Stefano Grosso; Francesca Molinari; Teresa Macarulla; Mariangela Russo; Carlotta Cancelliere; Davide Zecchin; Luca Mazzucchelli; Takehiko Sasazuki; Senji Shirasawa; Massimo Geuna; Milo Frattini; José Baselga; Margherita Gallicchio; Stefano Biffo; Alberto Bardelli
Journal:  J Clin Invest       Date:  2010-07-26       Impact factor: 14.808

5.  PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Authors:  Filip Janku; Jennifer J Wheler; Aung Naing; Gerald S Falchook; David S Hong; Vanda M Stepanek; Siqing Fu; Sarina A Piha-Paul; J Jack Lee; Rajyalakshmi Luthra; Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  Cancer Res       Date:  2012-10-12       Impact factor: 12.701

6.  Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Authors:  Nathan T Ihle; Robert Lemos; Peter Wipf; Adly Yacoub; Clint Mitchell; Doris Siwak; Gordon B Mills; Paul Dent; D Lynn Kirkpatrick; Garth Powis
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

7.  PIK3CA mutations in advanced cancers: characteristics and outcomes.

Authors:  Filip Janku; Jennifer J Wheler; Aung Naing; Vanda M Stepanek; Gerald S Falchook; Siqing Fu; Ignacio Garrido-Laguna; Apostolia M Tsimberidou; Sarina A Piha-Paul; Stacy L Moulder; Jack J Lee; Rajyalakshmi Luthra; David S Hong; Razelle Kurzrock
Journal:  Oncotarget       Date:  2012-12

8.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440
  8 in total
  2 in total

Review 1.  Targeted therapies for advanced Ewing sarcoma family of tumors.

Authors:  Yunyun Jiang; Joseph Ludwig; Filip Janku
Journal:  Cancer Treat Rev       Date:  2015-03-27       Impact factor: 12.111

2.  Functional exploration of colorectal cancer genomes using Drosophila.

Authors:  Erdem Bangi; Claudio Murgia; Alexander G S Teague; Owen J Sansom; Ross L Cagan
Journal:  Nat Commun       Date:  2016-11-29       Impact factor: 14.919
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.